Clinical Information (ข้อมูลทางคลินิก):
CA 125 II assay values are defined by using the OC 125 monoclonal antibody. OC 125 was generated through the hybridization of mouse myeloma cells to spleen cells from a mouse immunized with a human
serous cystadenocarcinoma cell line called OVCA 433. ARCHITECT CA 125 II is a second-generation assay for the detection of OC 125 defined antigen. The assay utilizes the OC 125 monoclonal antibody, as the capture antibody coated onto paramagnetic microparticles that bind molecules containing OC 125 defined antigen.
These defined antigens are quantified using acridinium-labeled M11 antibody. The OC 125 monoclonal
antibody is reactive with repeating OC 125 defined antigen expressed by a high percentage of nonmucinous ovarian carcinomas (serous, endometrioid, clear cell, and undifferentiated histologies) and epithelial ovarian carcinoma cell lines. OC 125 defined antigens were originally detected in normal peritoneal, pleural and pericardial tissues of both fetus and adult. In the fetus, OC 125 defined antigens have been localized in
amniotic and umbilical epithelial and Müllerian epithelial tissues. In the adult, localization has been identified in endocervical and endometrial tissues and ovarian inclusion cysts and papillary excrescences. However,
OC 125 defined antigens were not detected in fetal ovarian tissue or other normal adult ovarian tissues or benign mucinous ovarian tumors. In serum, the OC 125 defined antigens are associated with high molecular
weight glycoproteins heterogeneous in size and charge. The structure of the CA 125 molecule, including closely situated repeating epitopes for OC 125 and M11 antibodies has been proposed.
Serum CA 125 II assay values are useful for monitoring the course of disease in patients with invasive epithelial ovarian cancer. In a review of nine published studies, the overall correlation reported between
CA 125 serum levels and the course of the disease was 87%. Persistently rising CA 125 assay values may be associated with malignant disease and poor response to therapy, whereas decreasing CA 125 assay values may indicate a favorable response to therapy.
A second-look, exploratory laparotomy may have been performed previously to assess response to therapy. The benefit has recently come into question because of high morbidity and low sensitivity in detecting
residual or recurrent carcinoma. In women with primary epithelial ovarian carcinoma who had undergone first-line therapy and were candidates for diagnostic second-look procedures, a CA 125 assay value greater than or
equal to 35 U/mL was found to be indicative of the presence of residual tumor. However, a CA 125 assay value below 35 U/mL does not indicate the absence of residual ovarian cancer because patients with histopathologic evidence of ovarian carcinoma may have CA 125 assay values within the range of normal individuals.
Clinical Reference (เอกสารอ้างอิง):
Manufacturer’s Reagent package insert Architect CA 125 II, November 2015, Abbott Laboratories, Diagnostic Division, Abbott Park IL 60064 USA.